About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Another Vote Against Rhodanines | Main | How Come? »

May 23, 2012

Drug Discovery on Radio 4

Email This Entry

Posted by Derek

Several readers sent along a link to this Radio 4 program ("The End of Drug Disocvery") from the BBC on drug discovery. From what I've heard, it's a very good overview of the current state of the field for people outside it, and gets across just how difficult it's been to find good drug candidates.

Comments (4) + TrackBacks (0) | Category: Press Coverage


1. petros on May 23, 2012 10:09 AM writes...

Had missed this so thanks for the plug Derek.

An interesting set of interviewees including
Chas Bountra (Structural Genomics Consortium)
Patrick Vallance (GSK)
Paul Workman

Also had a non-pharma academic claiming that the use of stem cells will deliver human tissue for all sorts of tox studies!

Permalink to Comment

2. Anonymous on May 23, 2012 10:16 AM writes...

Nice overview, even if a bit basic for the readership here. Great to hear Patrick Vallance speak so eloquently and with such evident erudition. Patrick has been very supportive of pre-competitive alliances, just check out the game-changing Pistoia Alliance for a working example of this where GSK is one of the main drivers!

Permalink to Comment

3. DrSnowboard on May 23, 2012 5:00 PM writes...

@2 Nice summary, even if a bit obvious and toadying for the readership here. Great to hear your unbiased and gushing praise of 'Patrick', we all call him by his first name here, just check out my previous game-changing press releases..err I mean posts on the GSK internal blogs!

Permalink to Comment

4. johnnyboy on May 23, 2012 8:03 PM writes...

@3: you have stumbled upon The Commenter Formerly Known as Agilist, and lord knows how many other pseudonyms. He pops up here every single time something about GSK is mentioned, to toot the company's horn. Obviously the GSK cuts haven't fully affected the PR department yet.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry